Drug Trial Radar · NCT00574249
Adalimumab in Combination With Topical Treatment (Calcipotriol/Betamethasone) in Subjects With Moderate to Severe Psoriasis and Insufficient Response to Classic Systemic Treatment
Last checked: Nov 19, 2026Latest source record: Apr 13, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
730
Actual
Start
Nov 2007
Primary completion
Oct 2008
Sponsor
- Lead sponsor
- AbbottIndustry
- Sponsor type
- Industry
- First posted
- Dec 17, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the efficacy and safety of adalimumab in combination with topical psoriasis treatment, calcipotriol/betamethasone, vs. adalimumab in combination with matching vehicle in subjects with moderate to severe chronic plaque psoriasis.
Conditions
- Chronic Plaque Psoriasis
Interventions
adalimumabBiological
subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15
Calcipotriol/Betamethasone OintmentDrug
Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
placebo (vehicle ointment)Drug
Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieve a PASI75 Response at Week 16 Compared With Baseline (Week 0)Time frame: Week 0 and Week 16
Locations
131 sites in 15 countries. Site status is shown where the registry gives one.
Site not named
Graz, Austria
Site not named
Innsbruck, Austria
Site not named
Salzburg, Austria
Site not named
Vienna, Austria
Site not named
Vienna, Austria
Site not named
Wein, Austria
Site not named
Aalst, Belgium
Site not named
Bruges, Belgium
Site not named
Brussels, Belgium
Site not named
Brussels, Belgium
Site not named
Brussels, Belgium
Site not named
Edegem, Belgium
Site not named
Geel, Belgium
Site not named
Ghent, Belgium
Site not named
Kortrijk, Belgium
Site not named
Leuven, Belgium
Site not named
Liège, Belgium
Site not named
Mons, Belgium
Site not named
Brno, Czechia
Site not named
Hradec Králové, Czechia
Site not named
Prague, Czechia
Site not named
Arhus C, Denmark
Site not named
Copenhagen, Denmark
Site not named
Hellerup, Denmark
Site not named
Herning, Denmark
Site not named
Helsinki HUS, Finland
Site not named
Jyväskylä, Finland
Site not named
Lahti, Finland
Site not named
Brest, France
Site not named
Créteil, France
Site not named
Lille, France
Site not named
Limoges, France
Site not named
Montpellier, France
Site not named
Nancy, France
Site not named
Nice, France
Site not named
Paris, France
Site not named
Pessac, France
Site not named
Pierre-Bénite, France
Site not named
Rouen, France
Site not named
Saint-Etienne, France
Showing 40 of 131 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.